Eur Heart J:他汀类药物的负面新闻可增加患者心脏病的发生风险

2015-12-04 MedSci MedSci原创

据发表于European Heart Journal的一项新的研究表明,人们正面临着来自于他汀类药物所带来的不利健康影响,研究显示停药治疗会增加患者心脏病和早逝的发生风险。他汀类药物曾被认为是最安全的药物之一,也是目前预防心血管疾病最有效的药物。然而,他汀类药物也存在副作用,尤其是用药的前6个月内,包括肌痛和横纹肌溶解(十分罕见

据发表于European Heart Journal的一项新的研究表明,人们正面临着来自于他汀类药物所带来的不利健康影响,研究显示停药治疗会增加患者心脏病和早逝的发生风险。

他汀类药物曾被认为是最安全的药物之一,也是目前预防心血管疾病最有效的药物。然而,他汀类药物也存在副作用,尤其是用药的前6个月内,包括肌痛和横纹肌溶解(十分罕见)。对这些副作用的恐惧使得患者在早期便终止了其药物治疗。

Prof. Nordestgaard及其同事Dr. Sune Nielsen探究了他汀类药物的负面消息如何影响患者是否继续药物治疗的决定。

该研究纳入了674900名40岁及以上的患者,这些患者在1995年1月至2010年12月间服用过他汀类药物,追踪观察这些患者至2011年底。此外,研究人员还确定了自1995年1月开始的1931条他汀类相关的新闻,并进行分级:负面的(110条);中立的(1090条);正面的(731条)。

此外,研究人员还分析了他汀类药物的使用与心血管疾病或糖尿病之间的关系,包括药物开始使用的时间,使用的时间,药物剂量,性别,居住城市以及种族。

每一条负面新闻增加9%的停用风险。

1995-2010年,人们使用他汀类药物的比例从不足1%增加到11%,然而早期停药的比例也从6%增加到18%。

所有关于他汀类药物的新闻(正面的、中立的、负面的)的数量从1995年的30条增加至2009年的400条,而且每条关于他汀类药物降低胆固醇药物组的负面的全国性新闻可增加9%的停药风险(使用他汀类药物前6个月内停药)。

早期停药的风险也相应变高,每多使用一年(4%),增加每日用药剂量(4%),男性(5%),住在城市(13%),非丹麦人种(67%)。

相反的,正面新闻报道后则他汀类药物的停药风险下降(8%),使得患者患心血管疾病(27%)或糖尿病(9%)时首先应用他汀类药物。

Prof. Nielsen说道:

“williamhill asia 发现他汀类药物的负面新闻与早期停用他汀类药物有关,并且还可解释2%心脏病发作和1%的心血管疾病死亡与早期停用他汀类药物有关的原因。与继续服用他汀类药物的患者相比,早期停用他汀类药物的患者其心脏病发作的风险增加了26%,心血管疾病致死的风险增加了18%。”

尽管还不确定是否是因为负面新闻导致了患者停用他汀类药物,但是有研究表明二者之间或存在关联;并且有迹象表明早期停药或可导致的不必要的心脏病发作和死亡的发生。

作者强调有必要坚持用药并面对心血管疾病问题,提倡使用更多的方法来鼓励患者继续用药。

Prof. Nordestgaard称,必须采取措施来确保人们继续坚持治疗,尤其是在使用他汀类药物最初的6个月内。

正面的新闻通常是基于循证的基础,可解释他汀类药物如何能够预防心脏病发作及早逝的发生。相反,负面的新闻则侧重于相对地极少的且比较温和的副作用。

最后,作者总结道,如果没有他汀类相关的负面的新闻,那么将会有1.3%的患者继续服用他汀类药物。

原始出处:

Yvette Brazier. Negative statin stories add to heart health risk. MNT, 2 December 2015.

Fallgaard Nielsen et al.. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Sune European Heart Journal, doi:10.1093/eurheartj/ehv641, published 2 December 2015.

Quiping Gu et al.. Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003–2012. National Center for Health Statistics Data Brief, accessed 1 December 2015 via CDC.

European Society of Cardiology (ESC) news release, accessed 1 December 2015 via AlphaGalileo.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2016-01-09 medsic

    奇怪,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2016-01-09 medsic

    这样………

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2016-01-09 medsic

    额…

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-27 hixiaoluo

    好文章,值得收藏

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-20 campus

    可怕(⊙o⊙)

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-07 李思思

    还是不懂

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-06 sanshengshi

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-06 heli0118
  10. [GetPortalCommentsPageByObjectIdResponse(id=2044388, encodeId=fca220443889c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Mar 31 01:53:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55351, encodeId=3f2c5535150, content=奇怪,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55352, encodeId=2976553524f, content=这样………, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:22:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55350, encodeId=d61555350f2, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:21:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48897, encodeId=31dc4889e62, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46862, encodeId=fc7a4686239, content=可怕(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ae86106, createdName=campus, createdTime=Sun Dec 20 18:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45096, encodeId=60f845096f8, content=还是不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a63a1668977, createdName=李思思, createdTime=Mon Dec 07 17:02:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44990, encodeId=572344990a2, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Dec 06 20:14:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356041, encodeId=c58e1356041c0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562342, encodeId=9f79156234269, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Dec 06 11:53:00 CST 2015, time=2015-12-06, status=1, ipAttribution=)]
    2015-12-06 slcumt

相关威廉亚洲官网

PLoS One:他汀类药物或可降低LOD患者的痴呆风险

相关研究报道,晚发抑郁障碍(LOD)患者患继发痴呆的风险较高。本研究对他汀类药物是否可以降低LOD患者的痴呆风险进行了评估。 研究人员纳入了来自台湾地区健康保险管理数据,时间为1996-2009年。通过标准化发生率(SIRs)评估晚发抑郁障碍(LOD)和继发痴呆。LOD诊断标准:年龄≥65岁,65岁后诊断为抑郁障碍,并有至少3次的服务需求,同时服用抗抑郁药物。通过Cox比例风险模型多变量分析

Gastroenterology:他汀类药物对代偿性肝硬化患者的影响

他汀药物治疗可降低肝硬化患者的门静脉压以及增加静脉曲张伴返伴流时间。他汀药物可能具有肝毒素性作用,所以确定长期使用他汀对肝硬化患者是否有害是很重要的事。本研究旨在评估他汀类药物对代偿性肝硬化患者的影响。 研究人员根据退伍军人临床病例注册进行了一项回顾性队列研究,研究对象来自于全国范围内的丙型肝炎病毒(HCV)患者。研究人员纳入了来自1996年1月到2009年12月代偿性肝硬化患者。依据所开的处方

Neurology:他汀类药物可降低卒中后癫痫发作风险

本研究评估了他汀类药物治疗卒中后癫痫发作的风险。 在这项单中心、队列研究中,收纳了初发缺血性脑卒中并且无癫痫中风史的患者。经过2.5年的平均随访,评估并确定卒中后癫痫发作的风险。通过逻辑回归和Cox回归分析评估了他丁药物与脑卒中后早发性癫痫发作(ES)和脑卒中后癫痫(PSE)之间的关系。利用美国国立卫生研究院脑卒中量表(NIHSS)评估脑卒中严重程度:轻度(<7分)、中度(7~25分)、重度(>

Cell Metabolism:研究发现他汀类药物诱导肌病发生的机制

Cell Metabolism:研究发现他汀类药物诱导肌病发生的机制据发表于Cell Metabolism的一项新的研究表明,他汀类药物的使用或可增加肌无力及其相关副作用,其原因可能与药物影响了肌细胞内线粒体的功能有关。他汀类药物是一种常用的降胆固醇药物,可阻断肝脏中胆固醇的产生。胆固醇是心脏病和中风发生的一个主要危险因素,在美国三分之一的死亡病例源于中风和心脏病。据CDC统计,超过四分之一的40

JACC:冠状动脉钙化测试对于他汀类药物使用的影响

美国心脏病学学会(ACC)/美国心脏协会(AHA)的胆固醇管理威廉亚洲博彩公司 已经显著扩大了他汀类药物治疗合格候选者的范围。这项研究评估了冠状动脉钙化(CAC)缺乏对于那些来自于一个风险分层中重新分类的患者的影响,在这些分层中,一部分患者被建议使用他汀类药物,一部分不被建议使用他汀类药物。MESA(动脉粥样硬化的多种族研究)研究是一项包括是45至84岁的6814名男性和女性的纵向研究,这些参与者在招募时没有临

Circulation:糖尿病和高血压患者使用他汀类药物可抑制体内醛固酮的分泌

他汀类药物能够显著降低心血管病患者的死亡率,经研究发现,该类药物具有显著的降脂效果。由于他汀类药物对于心血管疾病具有显著疗效,因此研究人员假设他汀类药物可以调控醛固酮的分泌,之后,研究人员还对该假设进行了验证。研究人员在两项干预研究中测定了患者体内肾上腺素醛固酮的分泌水平。在对高血压患者的研究中,研究人员在患者分别处于基线水平以及以及在高钠和低钠食物中添加血管紧张素II对患者进行刺激的两种状态下测